Humana Inc. (HUM) Stock: Price, Forecast & Analyst Target
Humana Inc. (HUM) — MoonshotScore 79/100 (Strong band), calculated Nov 18, 2026. Price $380.00 (-1.50%), as of the Nov 19, 2026 trading session; market cap $45.6B. Expected results Feb 10, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Humana Inc. · HUM · NYSE · Healthcare · Medical - Healthcare Plans
Research dated 2026-09-12: Humana combines health-plan underwriting with CenterWell pharmacy, provider-network and home-based care services, selling coverage directly while also serving government programs, employers and outside clients. The case depends on whether Medicare Advantage bid choices and membership mix can restore durable margins without sacrificing the revenue base that supports Humana’s care-delivery network.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Humana (HUM)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, though the balance sheet and growth are only middling; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- EPS beat 7 of the last 8 reports
- expected results Feb 10, 2027
- Altman Z 4.78 · Piotroski F 8
Helping: business quality, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 76 | Strong | |
| 77 | Strong | |
| 76 | Strong | |
| 76 | Strong | |
| 79 | Strong | |
| 79 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $380.00 | |
| Change on the day | -1.50% | |
| 52-week range | $163.11–$462.87 | |
| Market capitalisation | $45.6B | — |
| Price / earnings (trailing) | 42.72 | |
| Shares traded on the day | 1.94M | |
| Beta (volatility vs the S&P 500) | 0.74 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Humana (HUM): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Simons-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Humana (HUM), and what does it report?
Short answer · as of
Humana is primarily an insurer, but premium revenue is only part of the operating picture.
Research dated 2026-09-12.
Its Insurance segment covers individual medical and supplemental plans, state-sponsored benefits, employer coverage, administrative services and military health support, while CenterWell supplies pharmacy management, provider-network services and home-based care to Humana members and external customers.
Reported revenue therefore measures both health-plan activity and care-service activity. Insurance remains the much larger segment, so consolidated growth can coexist with weak earnings when the spread between plan revenue and medical and operating costs narrows; CenterWell adds a service platform, but does not displace underwriting as the dominant economic engine.
What do the latest results show for Humana (HUM)?
Research dated 2026-09-12.
The latest period extended a sharp revenue advance and remained profitable, but net income, operating income and gross profit all eased from the preceding period. That combination points to continuing volume or premium expansion alongside less favorable profit conversion, rather than a simple contraction in demand.
Reported revenue and earnings came in above expectations, continuing a run in which earnings repeatedly cleared estimates even when statutory results included period-end losses. Management is linking future margin progress to Medicare Advantage bids and to the eventual size and composition of membership; that is an outlook, not yet an explanation proven by the reported margin series.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $41.16B Nov 6, 2026
- Latest report · revenue estimate
- $40.87B Nov 6, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 6, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 6, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 6, 2026 | $41.16B | $40.87B | −$0.7000 | −$1.0000 |
| Jul 29, 2026 | $40.87B | $40.58B | $7.6100 | $7.2700 |
| Apr 29, 2026 | $39.65B | $39.37B | $10.3100 | $10.2400 |
| Feb 11, 2026 | $32.52B | $32.04B | −$3.9600 | −$4.0000 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $32.65B | $195M | $1.61 (diluted) |
| Q4 FY2025 | $32.52B | -$796M | — |
| Q1 FY2026 | $39.65B | $1.19B | $9.83 (diluted) |
| Q2 FY2026 | $40.87B | $694M | $5.73 (diluted) |
What are the financial strengths and risks for Humana (HUM)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Humana’s cash and short-term investments exceed total debt, leaving a substantial net cash position on the stated liquidity basis. The balance is also far above its recent level, while the quality and distress screens remain constructive.
Cash generation is much less settled than the balance-sheet snapshot suggests. Operating cash flow has swung sharply between inflows and outflows, the latest period was negative, and trailing free-cash-flow yield was below zero; meanwhile, thin net and operating margins leave earnings highly sensitive to medical-cost pressure or bid decisions that fail to price the enrolled population adequately.
What should you watch next at Humana (HUM)?
Short answer · as of
The next earnings report is expected on Feb 10, 2027.
Research dated 2026-09-12.
Watch whether revenue can hold near its recently elevated run rate while operating profit and cash flow recover together. Revenue growth without better conversion would reinforce the concern that Humana is adding premium or service volume faster than it is rebuilding economics.
The approaching earnings release carries an expectation of a loss despite roughly stable revenue, making the mix of membership and the profitability of that book more informative than the top line alone. Beyond that release, progress should appear through wider margins and steadier cash generation before management’s Medicare Advantage bid strategy can be treated as delivered.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Humana compare with its peers?
Short answer
Humana's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Humana differs from a health plan whose economics end with collecting premiums and paying claims. CenterWell places pharmacy, provider-network and home-based care inside the same corporate system, and those services can also serve outside clients.
That structure creates more ways to participate in member care, but it does not make Humana a broadly diversified healthcare conglomerate: Insurance still contributes the dominant share of segment revenue. Compared with more balanced managed-care peers, Humana’s results remain especially exposed to how Medicare Advantage bids translate into membership composition and underwriting margin.
| Company | Price | Market value | Score |
|---|---|---|---|
| $26.17 Nov 19, 2026 | $8.13B | 97 5-pillar Nov 18, 2026 | |
| $403.60 Nov 18, 2026 | $46.1B | 96 5-pillar Nov 18, 2026 | |
| $3.77 Nov 19, 2026 | $2.02B | 94 5-pillar Nov 18, 2026 | |
| $65.62 Nov 19, 2026 | $32.5B | 91 5-pillar Nov 18, 2026 | |
| $390.16 Nov 19, 2026 | $84.3B | 88 5-pillar Nov 18, 2026 | |
| $175.34 Nov 19, 2026 | $49.4B | 83 5-pillar Nov 18, 2026 | |
| $80.06 Nov 19, 2026 | $102B | 81 5-pillar Nov 18, 2026 | |
| $74.52 Nov 19, 2026 | $35.8B | 80 5-pillar Nov 18, 2026 | |
| Humana (HUM) — this page | $380.00 | $45.6B | 79 |
| $273.09 Nov 19, 2026 | $72.0B | 78 5-pillar Nov 18, 2026 | |
| $349.91 Nov 18, 2026 | $314B | 76 5-pillar Nov 18, 2026 | |
| $9.08 Nov 18, 2026 | $39.8B | 75 5-pillar Nov 18, 2026 | |
| $6.72 Nov 18, 2026 | $1.41B | 73 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $300.00 – $596.00
- Consensus target
- $483.74
- Median target
- $495.00
Consensus record · Captured .
Measured against a quoted price of $380.00 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 9
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 2
- Other transactions
- 7
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held HUM in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0.56% | $24.89M | New position |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
HUM Healthcare Stock FAQ
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do Medicare Advantage bids affect Humana’s margins?
Bid choices shape the benefits, pricing and membership Humana attracts, so they influence whether plan revenue adequately covers medical and operating costs. Management expects its bidding approach to advance margin recovery, with actual results dependent on membership size and composition.
What does CenterWell contribute to Humana beyond insurance?
CenterWell provides pharmacy management, provider-network support and home-based care for Humana plan members and external clients. It broadens Humana’s participation in care delivery, although Insurance remains the larger reported revenue engine.
Why can Humana’s revenue rise while its profit weakens?
Premium and service volume can expand even when medical and operating costs absorb more of the revenue. Humana’s recent annual and quarterly record shows exactly that tension: a larger top line has not produced a comparable improvement in net results or margins.
How does Humana’s government business differ from its employer coverage?
Government-linked operations include Medicare-related prescription support, state Medicaid and long-term-care arrangements, and military health services. Employer offerings include insured medical and specialty benefits as well as administrative-services arrangements, giving Humana different revenue and risk relationships across customer groups.
What is the HUM stock price today?
The last price recorded for Humana Inc. (HUM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the HUM price target?
The analyst consensus price target for Humana Inc. (HUM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 34 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com